HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized, controlled, registrational Phase II study of the company's novel drug candidate, olverembatinib (R&D code: HQP1351), in.
Zai Lab Limited (ZLAB) Announces First Listing of VYVGART, Other Updates in China's National Reimbursement Drug List streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
China Medical System: 4 Products Have Been Newly Included globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Hutchmed Ltd on Wednesday said it has completed enrolment of its phase II/III trial of fruquintinib.
Hutchmed, a Hong Kong-based developer of treatments for cancer and immunological diseases, said.